Search Results for:Crystal Tse
More than 10 biotech companies have applied to begin trading on the Hong Kong stock exchange since the bourse changed its rules in April to allow unprofitable drug developers to join.
A $1 billion deal would be the largest consumer IPO this year in Hong Kong, which has been focused on transforming itself into a hub for fundraising by new-economy companies
A successful listing would be a landmark event for the crypto industry, which is increasingly trying to move from the fringes of finance into the mainstream.
Suzhou Kintor Pharmaceuticals Inc. and Frontier Biotechnologies are planning Hong Kong stock offerings that could each raise about $300 million.
Companies including Xiaomi Corp. and China Tower Corp. have completed $19.2 billion of first-time share sales since the beginning of June
I-Mab has attracted capital from some China’s most active private equity investors including Hony Capital, Hopu Investment Management and Hillhouse Capital.
A wider range of health-care companies are planning to list in Hong Kong after the city’s bourse relaxed rules earlier this year to allow IPOs from pre-profit biotech firms.
Hillhouse funds and Taobao China Holding Ltd. are among the 10 firms that agreed to buy about $1.4 billion of stock as cornerstone investors
Chinese startups continue to seek stock offerings in the U.S. even as the Hong Kong bourse has started attracting a wider range of tech and health-care firms
GIC has agreed to buy $75 million of stock.